Drug Profile
Research programme: anticancer monoclonal antibodies - Eisai Inc
Alternative Names: Humanised mAbs for cancer - Morphotek/National Cancer Institute (NCI); MORAb-050Latest Information Update: 23 Jan 2020
Price :
$50
*
At a glance
- Originator Morphotek
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Malignant melanoma
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Malignant-melanoma(Metastatic disease) in USA (Parenteral)
- 08 Jul 2013 Preclinical trials of MORAb 050 in Malignant melanoma (metastatic disease) in USA (Parenteral)